Celltrion, Inc. Stock price

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 07:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
191,200 KRW +4.03% Intraday chart for Celltrion, Inc. +2.91% -5.11%
Sales 2024 * 3,462B 2.57B Sales 2025 * 4,114B 3.05B Capitalization 38,097B 28.27B
Net income 2024 * 628B 466M Net income 2025 * 1,123B 833M EV / Sales 2024 * 11.5 x
Net Debt 2024 * 1,628B 1.21B Net Debt 2025 * 1,536B 1.14B EV / Sales 2025 * 9.63 x
P/E ratio 2024 *
60 x
P/E ratio 2025 *
33.4 x
Employees 2,034
Yield 2024 *
0.2%
Yield 2025 *
0.23%
Free-Float 67.17%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.22%
1 week-1.08%
Current month+2.28%
1 month-3.26%
3 months-8.78%
6 months+32.04%
Current year-8.78%
More quotes
1 week
180 300.00
Extreme 180300
192 400.00
1 month
172 300.00
Extreme 172300
192 400.00
Current year
172 300.00
Extreme 172300
241 000.00
1 year
131 000.00
Extreme 131000
241 000.00
3 years
131 000.00
Extreme 131000
311 085.97
5 years
121 026.29
Extreme 121026.2888
372 915.00
10 years
27 751.54
Extreme 27751.5426
372 915.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 07-04-23
Director of Finance/CFO 49 -
Chairman 66 -
Members of the board TitleAgeSince
Director/Board Member 73 -
Chairman 66 -
Director/Board Member 71 14-12-07
More insiders
Date Price Change Volume
24-03-28 191,200 +4.03% 1 422 950
24-03-28 183,800 -0.22% 896,928
24-03-27 184,200 -1.18% 644,326
24-03-26 186,400 -1.32% 690,399
24-03-25 188,900 +0.37% 646,054

End-of-day quote Korea S.E., March 27, 2024

More quotes
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
183,800 KRW
Average target price
221,118 KRW
Spread / Average Target
+20.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Celltrion, Inc. - Korea S.E.